← All candidates
65 insider filings on record.
65 filings on record.
XERSXeris Biopharma Holdings, Inc.
NasdaqGS · Healthcare · $1.50B
$8.20
+0.49% · Sep 18
65 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 18 sells◆ 3 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.50B
Float
176.0M
97% public
Short % float
Pro
Price / profit
115.4
Price / future profit
21.0
Price / sales
4.5
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
See Remarks
McCulloch Kevin
Bought $109.5K on Jun 13 — 25,000 sh @ $4.38, held direct, 1.5% of their stake.
1 of 1 position beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
60 more transactions on Pro →Context
Wall St
$11.29 avg target
+37.6% vs today · 7 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26$0.01 act+$0.01
Q4 '25$0.06 act+$0.01
Q3 '25$0.00 act−$0.00
Q2 '25−$0.01 act+$0.02
Coverage
Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?Insider Monkey · 06-30Jim Cramer Blesses a Caller’s Speculative Investment in Xeris BiopharmaInsider Monkey · 06-12Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) EarningsSimply Wall St. · 05-15Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise ProfitSimply Wall St. · 05-09
The file stays open
65 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice